Results 201 to 210 of about 18,595 (356)

Inclisiran: A Systematic Review Exploring the Revolutionary Approach of Twice-Yearly Dosing Regimen in the Treatment of Hypercholesterolemia. [PDF]

Cureus
Singareddy S, Dhakal S, Limbaña TA, Murugan V, Nazmin F, Garcia J, Khan S.   +6 more
europepmc   +1 more source

Plethora of adverse drug reactions in geriatric population receiving statin therapy for dyslipidaemia. [PDF]

J Family Med Prim Care, 2022
Padhye MR, Yadav NS.
europepmc   +1 more source

Studies on Mechanism of Hyperlipidemia

, 1978
Takahiko KAMOGAWA, Seiki NANBU, Shigemichi KAMIMOTO, Kazutora UEKI, Hironori Toshima, Noboru Kimura, Masato Ageta, R Suenaga, Seiichiro YAMASAKI   +8 more
openalex   +2 more sources

Pharmacokinetic and pharmacodynamic evaluation of sulbactam‐durlobactam in a critically ill patient on continuous venovenous hemofiltration infected with carbapenem‐resistant Acinetobacter baumannii‐calcoaceticus complex

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, EarlyView.
Abstract Background Drug databases currently do not provide dosing guidance for sulbactam‐durlobactam in continuous renal replacement therapy. Herein, we present the first in vivo pharmacokinetic (PK) evaluation of sulbactam‐durlobactam during continuous venovenous hemofiltration (CVVH) in a patient with carbapenem‐resistant Acinetobacter baumannii ...
Wesley D. Kufel, Nabil Zeineddine, Aliaa Fouad, Hanna F. Roenfanz, Ryan K. Shields, Ellen G. Kline, Jameson Warner, Kathleen Hanrahan, Joseph L. Kuti   +8 more
wiley   +1 more source

Cutaneous Manifestation in Hyperlipidemia

, 1979
Muneo Ohkido
openalex   +2 more sources

Real‐World Overall Survival Comparison of Enzalutamide and Abiraterone In First‐ and Second‐Line Setting of Metastatic Castration‐Resistant Prostate Cancer

The Prostate, Volume 85, Issue 12, Page 1151-1154, September 2025.
ABSTRACT Background While their indications overlap, no clinical trials have compared abiraterone and enzalutamide for overall survival (OS) in mCRPC. Methods A large, country‐wide health insurance database (2013‐2023) was assessed for the OS comparison between abiraterone and enzalutamide. Results Overall, 3497 patients were identified with first‐ (n =
András Horváth, Celia Blasszauer, Ida Komka, Dániel Reibl, Boris Hadaschik, Tamás Fazekas, Pawel Rajwa, Àron Soós, Anikó Valikovics, Péter Nyirády, Tibor Szarvas   +10 more
wiley   +1 more source

Are Dyslipidemias a risk factor for Peri-Implant complications? A Systematic review and meta-analysis. [PDF]

J Clin Exp Dent
Gurgel B, Souza R, Vajgel A, Cabral MF, Almeida M, Almeida R.   +5 more
europepmc   +1 more source

Association between lithium use and the incidence of dementia and its subtypes: A retrospective cohort study. [PDF]

PLoS Med, 2022
Chen S, Underwood BR, Jones PB, Lewis JR, Cardinal RN.   +4 more
europepmc   +1 more source

Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia

, 1983
John D. Brunzell, J J Albers, Alan Chait, S M Grundy, Elliott Groszek, GB McDonald   +5 more
openalex   +1 more source

An Up‐to‐Date Review of Traditional Chinese Medicine in the Treatment of Atherosclerosis: Components, Mechanisms, and Therapeutic Potentials

Phytotherapy Research, EarlyView.
Traditional Chinese medicine in atherosclerosis: multi‐target modulation of pathogenesis. ABSTRACT Atherosclerosis is a chronic inflammatory disease and a major global health concern. In recent years, traditional Chinese medicines (TCMs) have demonstrated multi‐target therapeutic potential against atherosclerosis by modulating inflammatory responses ...
Dilaram Nijat, Qingzhe Zhao, Gulhasal Abdurixit, Jianhua He, Haipeng Liu, Jinyao Li   +5 more
wiley   +1 more source